uniQure NV
Gesloten
48.16 79.84
Overzicht
Wijziging aandelenprijs
24u
Min
26.93
Max
49.68
Inkomsten | -16M -54M |
|---|---|
Verkoop | -2M 3.6M |
EPS | -0.73 |
Winstmarge | -1,502.948 |
Werknemers | 221 |
EBITDA | 13M -36M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +47.76% upside |
Volgende Winsten | 28 jul 2026 |
|---|
Marktkapitalisatie | 454M 1.8B |
|---|---|
Vorige openingsprijs | -31.68 |
Vorige sluitingsprijs | 48.16 |
uniQure NV Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
